摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3,3-dimethyl-2-oxocyclohexanecarbonitrile | 10219-83-7

中文名称
——
中文别名
——
英文名称
3,3-dimethyl-2-oxocyclohexanecarbonitrile
英文别名
6-Cyan-2,2-dimethyl-cyclohexanon;3,3-Dimethyl-2-oxocyclohexane-1-carbonitrile
3,3-dimethyl-2-oxocyclohexanecarbonitrile化学式
CAS
10219-83-7
化学式
C9H13NO
mdl
MFCD21338517
分子量
151.208
InChiKey
LYOMCTAJOYDNIW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    11
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.777
  • 拓扑面积:
    40.9
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    3,3-dimethyl-2-oxocyclohexanecarbonitrile丁烯酮sodium ethanolate 作用下, 以 乙醇 为溶剂, 生成 8,8-Dimethyl-4a-cyan-2-oxo-Δ1(8a)-octalin
    参考文献:
    名称:
    二萜全合成,A→B→C方法—VI:10-氰基-12-羟基-7-氧代-17-北棕榈果-5,8,11,13-四烯,三环C-芳族二萜模型
    摘要:
    2,2-二甲基-6-羟基亚甲基环己酮(10)与盐酸羟胺的反应生成异构体异恶唑11和13的混合物。这些中较少的(13)是盐酸羟胺与异丙醇醚10的反应的排他产物,并被甲醇盐转化为6-氰基-2,2-二甲基环己酮(16)。此氰基酮(14)与甲基乙烯基酮和碱反应,以形成10-氰基-4,4-二甲基- Δ 5 -7- octalone(16),这是专门氢化成相应的反式-7-萘烷酮。
    DOI:
    10.1016/s0040-4020(01)90981-0
  • 作为产物:
    参考文献:
    名称:
    二萜全合成,A→B→C方法—VI:10-氰基-12-羟基-7-氧代-17-北棕榈果-5,8,11,13-四烯,三环C-芳族二萜模型
    摘要:
    2,2-二甲基-6-羟基亚甲基环己酮(10)与盐酸羟胺的反应生成异构体异恶唑11和13的混合物。这些中较少的(13)是盐酸羟胺与异丙醇醚10的反应的排他产物,并被甲醇盐转化为6-氰基-2,2-二甲基环己酮(16)。此氰基酮(14)与甲基乙烯基酮和碱反应,以形成10-氰基-4,4-二甲基- Δ 5 -7- octalone(16),这是专门氢化成相应的反式-7-萘烷酮。
    DOI:
    10.1016/s0040-4020(01)90981-0
点击查看最新优质反应信息

文献信息

  • [EN] BICYCLIC HETEROARYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS<br/>[FR] COMPOSÉS D'HÉTÉROARYLE URÉE, THIOURÉE,GUANIDINE ET CYANOGUANIDINE EN TANT QU'INHIBITEURS DE LA KINASE TRKA
    申请人:ARRAY BIOPHARMA INC
    公开号:WO2014078408A1
    公开(公告)日:2014-05-22
    Compounds of Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.
    式I化合物或其立体异构体、互变异构体或药学上可接受的盐、溶剂合物或前药,其中环A、环C和X如本文所定义,是TrkA激酶的抑制剂,并且在治疗可以用TrkA激酶抑制剂治疗的疾病中具有用处,如疼痛、癌症、炎症/炎症性疾病、神经退行性疾病、某些传染病、干燥综合征、子宫内膜异位症、糖尿病周围神经病变、前列腺炎和盆腔疼痛综合征。
  • [EN] N-(ARYLALKYL)-N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS<br/>[FR] COMPOSÉS DE N-(ARYLALKYLE)-N'-PYRAZOLYLE-URÉE, DE THIOURÉE, DE GUANIDINE ET DE CYANOGUANIDINE EN TANT QU'INHIBITEURS DE LA KINASE TRKA
    申请人:ARRAY BIOPHARMA INC
    公开号:WO2014078331A1
    公开(公告)日:2014-05-22
    Compounds of Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C, X, Ra, Rb, Rc, Rd and n are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.
    公式I的化合物或立体异构体、互变异构体、或药用可接受的盐、溶剂化物或前药,其中环A、环C、X、Ra、Rb、Rc、Rd和n如本文所述定义,是TrkA激酶的抑制剂,可用于治疗可以用TrkA激酶抑制剂治疗的疾病,如疼痛、癌症、炎症/炎症性疾病、神经退行性疾病、某些传染病、舍格伦综合症、子宫内膜异位症、糖尿病周围神经病变、前列腺炎或骨盆疼痛综合征。
  • [EN] BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN<br/>[FR] COMPOSÉS DE THIO-URÉE, GUANIDINE, CYNOGUANIDINE ET D'URÉE BICYCLIQUES UTILES POUR LE TRAITEMENT DE LA DOULEUR
    申请人:ARRAY BIOPHARMA INC
    公开号:WO2014078454A1
    公开(公告)日:2014-05-22
    Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.
    公式I的化合物:或立体异构体、互变异构体、或药用可接受的盐、溶剂化物或前药,其中环A、环C和X如本文定义,是TrkA激酶的抑制剂,可用于治疗可以用TrkA激酶抑制剂治疗的疾病,如疼痛、癌症、炎症/炎症性疾病、神经退行性疾病、某些传染病、舍格伦综合症、子宫内膜异位症、糖尿病周围神经病、前列腺炎和盆腔疼痛综合症。
  • [EN] THIAZOLYL AND OXAZOLYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS<br/>[FR] COMPOSÉS DE THIAZOLYL-URÉE, OXAZOLYL-URÉE, THIO-URÉE, GUANIDINE ET CYANOGUANIDINE EN TANT QU'INHIBITEURS DE LA KINASE TRKA
    申请人:ARRAY BIOPHARMA INC
    公开号:WO2014078322A1
    公开(公告)日:2014-05-22
    Compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.
    公式(I)的化合物或立体异构体、互变异构体、或其药物可接受的盐、溶剂化物或前药,其中环A、环C和X如本文定义,是TrkA激酶的抑制剂,并且可用于治疗可以用TrkA激酶抑制剂治疗的疾病,例如疼痛、癌症、炎症、神经退行性疾病、某些传染病、干燥综合征、子宫内膜异位症、糖尿病周围神经病变、前列腺炎或骨盆疼痛综合征。
  • [EN] N-(MONOCYCLIC ARYL),N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS<br/>[FR] COMPOSÉS DE N-ARYLE MONOCYCLIQUES, N'-PYRAZOLYL-URÉE, THIOURÉE, GUANIDINE ET CYANOGUANIDINE UTILES COMME INHIBITEURS DE TRKA KINASE
    申请人:ARRAY BIOPHARMA INC
    公开号:WO2014078325A1
    公开(公告)日:2014-05-22
    Compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.
    化合物的公式(I)或其立体异构体、互变异构体、或其药学上可接受的盐、溶剂合物或前药,其中环A、环C和X如本文所定义,是TrkA激酶的抑制剂,并且在治疗可以用TrkA激酶抑制剂治疗的疾病中具有用处,如疼痛、癌症、炎症/炎症性疾病、神经退行性疾病、某些传染病、干燥综合征、子宫内膜异位症、糖尿病周围神经病变、前列腺炎或盆腔疼痛综合征。
查看更多